MRNA Stock Analysis: Moderna Inc
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine
- Latest close
- $192.57
- 20-day change
- +24.83%
- Trend state
- BULLISH
- Classification
- Healthcare · Biotechnology
Market context
Moderna Inc moved +24.83% over the latest 20-session window. BullRecon currently classifies the broader setup as BULLISH.
Latest report
The latest cached company filing period (FY2025 · $1.9B revenue · -$2.8B net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Health is currently the strongest dimension at 4.6/6, while Profitability is the lowest at 0.5/6. Scores are comparative research signals, not forecasts.